These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8118750)

  • 21. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.
    de Valk-de Roo GW; Netelenbos JC; Peters-Muller IR; Voetberg GA; van de Weijer PH; Bouman AA; Popp-Snijders C; Kenemans P
    Maturitas; 1997 Dec; 28(2):153-62. PubMed ID: 9522323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
    Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin.
    Hartwell D; Hassager C; Overgaard K; Riis BJ; Pødenphant JR; Christiansen C
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):715-21. PubMed ID: 2375235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.
    Aerssens J; Van Audekercke R; Geusens P; Schot LP; Osman AA; Dequeker J
    Calcif Tissue Int; 1993 Oct; 53(4):269-77. PubMed ID: 8275356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nandrolone decanoate on bone mass in established osteoporosis.
    Passeri M; Pedrazzoni M; Pioli G; Butturini L; Ruys AH; Cortenraad MG
    Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
    Hassager C; Riis BJ; Pødenphant J; Christiansen C
    Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
    Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
    Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factors I and II in healthy women with and without established osteoporosis.
    Ravn P; Overgaard K; Spencer EM; Christiansen C
    Eur J Endocrinol; 1995 Mar; 132(3):313-9. PubMed ID: 7889180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anabolic steroids in corticosteroid-induced osteoporosis.
    Adami S; Rossini M
    Wien Med Wochenschr; 1993; 143(14-15):395-7. PubMed ID: 8256456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
    Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
    Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism.
    Møller S; Hansen M; Hillingso J; Jensen JE; Henriksen JH
    Gut; 1999 Mar; 44(3):417-23. PubMed ID: 10026331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Markers of bone formation and resorption in primary and secondary hyperparathyroidism].
    Kosowicz J; Baszko-Błaszyk D; Horst-Sikorska W; Ruszkowska J
    Pol Arch Med Wewn; 1998 Apr; 99(4):287-97. PubMed ID: 9760816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
    Beshyah SA; Kyd P; Thomas E; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and application of a serum C-telopeptide and osteocalcin assay to measure bone turnover in an ovariectomized rat model.
    Srivastava AK; Bhattacharyya S; Castillo G; Wergedal J; Mohan S; Baylink DJ
    Calcif Tissue Int; 2000 Jun; 66(6):435-42. PubMed ID: 10821880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.